Atlas Trials

Refractory T-Cell Non-Hodgkin Lymphoma

10 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory T-Cell Non-Hodgkin Lymphoma

RecordFirmDate
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas (NCT03925428)National Cancer Institute (NCI)2020-09-18
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03210662)M.D. Anderson Cancer Center2018-02-01
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625)National Cancer Institute (NCI)2017-09-27
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820)Mayo Clinic2017-04-04
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (NCT01921387)Fred Hutchinson Cancer Center2013-10-09
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (NCT01701986)M.D. Anderson Cancer Center2012-10-25
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT00860171)Fred Hutchinson Cancer Center2009-02-01

Track Refractory T-Cell Non-Hodgkin Lymphoma automatically

Every clearance here is in the API, with alerts when new ones post.